Who Should Not Use Tirzepatide
GLP-1 receptor agonists mimic natural hormones to enhance insulin secretion, suppress glucagon, slow gastric emptying and reduce appetite for diabetes and weight management
Step 3: NICE Assessment (For NHS Use) If MHRA approval is granted, the medicine may then be assessed by NICE to determine: Cost-effectiveness Eligible patient groups Prescribing criteria Whether the NHS funds it This stage mainly affects NHS availability, but private prescribing decisions may differ depending on the product licence
Her doctor reportedly told her that her binge eating and weight problems were "100% because [she] went on Ozempic." A 2025 review in eClinicalMedicine revealed that a substantial percentage of individuals with obesity who stop taking GLP-1s end up with larger waistlines and higher body mass indexes (BMIs) within 12 weeks
However, unlike natural GLP-1, which breaks down quickly in the body, semaglutide is designed to stay longer in circulation allowing once-weekly dosing
Moreover, this list is not exhaustive, and ongoing research continues to uncover additional contributors to neurodegeneration, emphasizing the complexity of ADRD pathophysiology and the need for specific prevention and intervention strategies